Human | GHRL | 51738 | ghrelin/obestatin prepropeptide | Several ghrelin gene variations were associated with blood pressure levels in subjects with impaired glucose tolerance |
Human | POLG2 | 11232 | polymerase (DNA directed), gamma 2, accessory subunit | Impaired glucose tolerance |
Human | PPARGC1A | 10891 | peroxisome proliferator-activated receptor gamma, coactivator 1 alpha | 482Ser allele of the PGC-1alpha gene is associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial |
Human | NAMPT | 10135 | nicotinamide phosphoribosyltransferase | The results indicate that hyperglycemia causes an increase in plasma visfatin levels and, as in people with diabetes mellitus type 2 but not with impaired glucose tolerance, this increase gets more prominent as the glucose intolerance worsens |
Human | ARHGEF11 | 9826 | Rho guanine nucleotide exchange factor (GEF) 11 | R1467H variant in the rho guanine nucleotide exchange factor 11 (ARHGEF11) is associated with impaired glucose tolerance and type 2 diabetes in German Caucasians |
Human | ADIPOQ | 9370 | adiponectin, C1Q and collagen domain containing | Impaired glucose tolerance (IGT) subjects had lower plasma adiponectin levels compared with normal(NGT) subjects Single nucleotide polymorphisms of the adiponectin gene as predictors for the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial, are evaluated Patients with impaired glucose tolerance (IGT) had significantly lower adiponectin levels than those with normal glucose tolerance; plasma adiponectin levels were associated with IGT in multiple logistic regression analysis single nucleotide polymorphism SNP276 of the adiponectin gene may affect impaired glucose tolerance and hypoadiponectinemia |
Human | AIP | 9049 | aryl hydrocarbon receptor interacting protein | Impaired glucose tolerance |
Human | TNFRSF1A | 7132 | tumor necrosis factor receptor superfamily, member 1A | Impaired glucose tolerance is not associated with increased serum concentrations |
Human | TNF | 7124 | tumor necrosis factor | Promoter polymorphism in this gene predicts the conversion from impaired glucose tolerance to type 2 diabetes Serum pro-inflammatory cytokine IL-6 or TNF-alpha concentrations were neither increased in subjects with impaired glucose tolerance nor closely correlated with the components of the metabolic syndrome |
Human | TCF7L2 | 6934 | transcription factor 7-like 2 (T-cell specific, HMG-box) | Common variants (rs12255372 and rs7903146) in TCF7L2 seem to be associated with an increased risk of diabetes among persons with impaired glucose tolerance The higher homeostasis model assessment insulin resistance index (HOMA-B%) index in TT-homozygotes indicates TCF7L2 to be a susceptibility gene for the development of impaired glucose tolerance in obese children |
Human | HNF1B | 6928 | HNF1 homeobox B | Impaired glucose tolerance |
Human | ABCC8 | 6833 | ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | Polymorphisms of SUR1 gene predicted conversion from impaired glucose tolerance to type 2 diabetes, and the effect of these polymorphisms on diabetes risk was additive with E23K polymorphism of Kir6.2 gene |
Human | SLC2A2 | 6514 | solute carrier family 2 (facilitated glucose transporter), member 2 | SNPs of SLC2A2 predict the conversion to diabetes in obese subjects with impaired glucose tolerance |
Human | RBP4 | 5950 | retinol binding protein 4, plasma | Plasma RBP4 concentrations were found to be elevated in subjects with impaired glucose tolerance or type 2 diabetes and to be related to various clinical parameters known to be associated with insulin resistance |
Human | PTPN1 | 5770 | protein tyrosine phosphatase, non-receptor type 1 | Title:A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose tolerance in Oji-Cree.|Association:Y|Conclusion:Not Found |
Human | PPARG | 5468 | peroxisome proliferator-activated receptor gamma | Pro12Pro genotype of the PPAR-gamma2 is associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial The proline allele at PPARG P12A increases risk for diabetes in persons with impaired glucose tolerance but has little or no effect on the beneficial response to troglitazone |
Human | PON1 | 5444 | paraoxonase 1 | Paraoxonase-1 L55M polymorphism is associated with an abnormal oral glucose tolerance test and differentiates high risk coronary disease families |
Human | SERPINE1 | 5054 | serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 | study demonstrates that PAI-1 concentrations are higher in impaired glucose tolerance than in normal glucose tolerance subjects |
Human | NPY | 4852 | neuropeptide Y | study provides the evidence that Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance (IGT) and type 2 diabetes in Swedish men |
Human | MTTP | 4547 | microsomal triglyceride transfer protein | the rare allele of the MTP I128T polymorphism may be protective against impaired glucose tolerance, type 2 diabetes and other parameters of the metabolic syndrome |
Human | LMNA | 4000 | lamin A/C | Impaired glucose tolerance |
Human | LEPR | 3953 | leptin receptor | relationship between the leptin receptor (OB-R) polymorphism and conversion from impaired glucose tolerance (IGT) to type 2 diabetes was not found but insertion allele was associated with reduction in weight, body mass index and waist circumference Title:|Association:Y|Conclusion: |
Human | ITGB2 | 3689 | integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) | Monocytic CD18 was elevated both in the diabetes and in the impaired glucose tolerance |
Human | INS | 3630 | insulin | Intrafollicular insulin levels were increased in women with impaired glucose tolerance |
Human | IL15 | 3600 | interleukin 15 | Associations between IL-15 serum level and long-term diabetic control lead to the speculation that IL-15 may serve as a target for future treatment in patients with prediabetes and/or for prevention of late diabetic complications |